DXR Daxor Corporation
USHealthcareAs of 2026-08-24
Why DXR matters now
Daxor Corporation (DXR) is a US stock in Healthcare. The latest InvestLog snapshot shows $9.77 with -2.30% on the session and $57.0M in market capitalization; recent performance reads 1-month -14.17% and YTD -33.90%.
The latest financial table shown here is Q4 2025, with revenue of $131.8K, net income of $9.5M, and EPS of $1.89. Investors can compare that operating picture with valuation signals such as P/E 4.91 and FCF yield 0.3%.
The latest indexable market news headline is "Daxor Broadens Outpatient Footprint with Initiation of ezBVA Lab Diagnostic Services in Kansas" from Globe News Wire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $23.00; recent insider activity includes Feldschuh Michael Richard filing P-Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
4.91
PEG
0.06
P/B
1.08
P/S
327.09
EV/EBITDA
5.16
DCF Value
$-0.03
FCF Yield
0.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
-57.5%
Operating Margin
6174.2%
Net Margin
6105.3%
ROE
22.5%
ROA
19.9%
ROIC
20.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $131.8K | $9.5M | $1.89 |
| FY 2025 | $503.4K | $9.2M | $1.84 |
| Q2 2025 | $18.3K | $-369.7K | $-0.07 |
| Q4 2024 | $695.3K | $2.2M | $0.44 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$23.00
Target (Median)
$23.00
Target Range
$23.00 - $23.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Country
US
Exchange
—
Beta
0.26
Based in Oak Ridge, Tennessee, Daxor Corporation is a medical technology enterprise founded in 1971. The company specializes in blood volume measurement, developing and commercializing the BVA-100 Blood Volume Analyzer. This diagnostic instrument offers a precise, objective method for quantifying a patient's blood volume status and composition, comparing these metrics against their unique physiological norms. It is utilized across a wide spectrum of medical and surgical contexts. Prior to May 1973, the organization operated under the name Idant Corporation.